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Abstract
Background: Estimates of month-2 culture conversion, a proxy indicator of tuberculosis (TB) treatment efficacy
in phase-2 trials can vary by culture-type and geographically with lower rates reported among African sites. The
sub-study aimed at comparing TB detection rates of different culture media, within and across rifampicin-based
regimens (R10, 15 and 20 mg/Kg) over a 6-month treatment follow-up period, and to establish predictors of
month-2 culture non-conversion among HIV-negative TB patients enrolled at RIFATOX trial site in Uganda.
Methods: Unlike in other Rifatox Trial sites, it is only in Uganda were Lowenstein-Jensen (LJ) and Mycobacteria
growth indicator tube (MGIT) were used throughout 6-months for treatment monitoring. Conversion rates were
compared at month-2, 4 and 6 across cultures and treatment-type. Binomial regression analysis performed for
predictors of month-2 non-conversion.
Results: Of the 100 enrolled patients, 45% had converted based on combined LJ and MGIT by month-2, with no
significant differences across treatment arms, p = 0.721. LJ exhibited higher conversion rates than MGIT at month-2
(58.4% vs 56.0%, p = 0.0707) and month-4 (98.9% vs 88.4%, p = 0.0391) respectively, more so within the high-dose
rifampicin arms. All patients had converted by month-6. Time-to-TB detection (TTD) on MGIT and social service jobs
independently predict month-2 non-conversion.
Conclusion: The month-2 culture conversion used in phase 2 clinical trials as surrogate marker of treatment
efficacy is influenced by the culture method used for monitoring mycobacterial response to TB treatment.
Therefore, multi-centric TB therapeutic trials using early efficacy endpoint should use the same culture method
across sites. The Time-to-detection of MTB on MGIT prior to treatment and working in Social service jobs bear an
increased risk of culture non-conversion at month-2.
Trial registration: ISRCTN ISRCTN55670677. Registered 09th November 2010. Retrospectively registered.
Keywords: Delayed culture conversion, Efficacy, HIV-negative TB patients, Time-to-detection, Treatment failure
Background
Culture conversion at month-2, is globally used as proxy
indicator of tuberculosis (TB) chemotherapy efficacy in
phase 2 clinical trials [1–3].
In addition to the treatment effect, several factors can
affect the culture conversion at month-2, such as genetic
polymorphism [4], age above 45 years, high pre-treatment
sputum bacterial load, drug resistance extent of the radio-
graphic involvement or presence of lung cavities, baseline
time-to-detection (TTD) of TB, infection with W-Beijing
genotype of M. Tuberculosis, smoking, and alcohol abuse
[5–10]. Treatment interruption, irregularity in drug intake,
and inadequate dosage, particularly of rifampicin may also
lead to delayed culture conversion [11–13]. This may ex-
plain variability of culture conversion at month-2 across
sites in multicenter clinical trials or amongst trials.
Although not much explored, the variations in culture
conversion may also be influenced by type of culture media
[3, 14]. Specifically, the solid culture medium (Löwenstein-
Jensen [LJ]) tend to exhibit a slower growth and lower sen-
sitivity as compared to liquid culture in a mycobacterium
growth indicator tube (MGIT) [1, 15]. There is no clear
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guidance whether both solid and liquid based culture media
should be used in tuberculosis clinical trials for outcome as-
sessment. This is particularly important for some sites from
high TB burden and limited resource countries which still
do have limited access to liquid culture medium. Therefore,
the impact of parallel use of different culture media within
the same geographical patient population on the outcome
evaluation of tuberculosis treatment regimen needs further
assessment.
We present results from a sub-study of the Rifatox trial
that evaluated the safety of high-dose rifampicin (R) (15
and 20 mg/Kg) administered during the first 4 months of
HIV negative TB patients’ treatment in Uganda, Nepal
and Bolivia [16].
This sub-study took advantage that within the Rifatox
trial, the Ugandan site used both LJ and MGIT cultures
for all patients during the 6 months treatment as per site
guidelines unlike other international sites that used LJ
alone and only up to month 2, so as to compare TB detec-
tion rates on different culture media, within and across
rifampicin-based treatment regimens over a 6-month




We conducted a secondary analysis of data of all 100 pa-
tients enrolled from the African site (Mbarara, Uganda)
within the Rifatox Trial [16].
Participants
The Mbarara site of the Rifatox trial was at Epicentre
Mbarara Research Centre and was the only African site.
The setting is endemic of TB and HIV. The trial consecu-
tively recruited participants from the outpatient department
(OPD) at Mbarara Regional Referral Hospital (MRRH).
Patients were eligible for enrolment in the trial if HIV
negative, aged 18 years and above, with two sputum sam-
ples positive for tubercle bacilli on microscopy; having re-
ceived less than a month of previous anti-tuberculosis
chemotherapy; with a firm and accessible home address
and if they consented to participation. Patients were ex-
cluded if they were critically ill, had extra-pulmonary TB,
alcoholism, psychiatric illness, blood disorders, diabetes,
epilepsy, HIV positivity, peripheral neuritis, pregnancy, a
hemoglobin <7 g/dl, serum ALT levels >5 times the upper
limit of normal (ULN), a creatinine clearance <30 ml/min,
and rifampicin resistance.
Study procedures
Socio-demographic characteristics specifically age, sex,
district of residence, marital status and occupation, were
collected using a standardized questionnaire which was
administered in the local language. All patients
underwent a physical examination by a medical doctor
to record clinical data.
Patients were randomized to one of the 3 treatment reg-
imens, that is: 1) Control Regimen (CR): 2 months of daily
ethambutol (E) isoniazid (H) pyrazinamide (Z) Z and R at
the usual dose of 10 mg/kg followed by 4 months of RH;
2) Study Regimen 1 (SR1):The regimen as above but with
an increase in the dose of R to 15 mg/kg body weight daily
for the first 4 months and a standard dose R (10 mg/kg)
was given for the last 2 months; 3) Study Regimen 2
(SR2): The regimen as in SR1 but with an increase in the
dose of R to 20 mg/kg body weight daily for the 4 months.
Treatment was given under Direct Observation (DOT) by
Domiciliary Treatment Monitor (DTM) or study nurse.
Patients provided spot sputum specimen at baseline,
months 2, 4 and 6 for smear microscopy, LJ and manual
MGIT (Becton, Dickinson, Franklin Lakes, NJ) cultures.
Resistance testing was performed on decontaminated
sample at baseline using GenoType MTBDRplus 2.0 (Hain
Lifescience, Nehren).
In the laboratory, the specimens were decontaminated
using the N-acetyl-L-cysteine and sodium hydroxide (1.5%
final concentration). The decontaminated sputum was in-
oculated into two homemade LJ medium tubes and one
MGIT tube. Negative culture results were reported after
56 days of incubation. Growth in the LJ and MGIT cul-
tures, were checked for Acid fast bacilli and contamin-
ation using Ziehl-Neelsen (ZN) microscopy and blood
agar culture respectively. ZN positive cultures were differ-
entiated between Mycobacterium tuberculosis (MTB) and
non-tuberculosis mycobacterium (NTM) using the SD TB
Ag MPT64 Rapid system (SD Bioline, Kyongi-do, South
Korea). Generally, the Time-to-positivity/detection was re-
corded for all TB patients using MGIT cultures.
Patients had weekly clinical assessment during first
2 months and then monthly with regular monitoring of
liver function tests [16].
Statistical analysis
Data were double-entered in a Voozanoo database (Epicon-
cept, Paris, France) and all statistical analysis was per-
formed using Stata® software (v. 12, College Station, Texas,
USA).
Relevant summary statistics were used to describe par-
ticipants’ baseline characteristics. The proportion of pa-
tients with culture conversion out of those with prior
baseline culture positivity was calculated at months-2, 4
and 6 by treatment regimen and by culture method (LJ,
MGIT and combination of LJ + MGIT) after exclusion
of patients with culture contaminated result from the
denominator. Patients with contaminated samples were
excluded in the subsequent analysis. Comparison of cul-
ture conversion between LJ and MGIT culture methods
at each time point was performed using Mc’ Nemar
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exact test for matched data, while Pearson Chi2 was
used to compare the culture conversion rates between
different treatment regimens used. Our dependent vari-
able was culture non-conversion at month-2, defined as:
having a MTB growth on either LJ or MGIT culture at
month-2. Independent variables used included: 1) base-
line patients’ socio-demographics (age, sex, district of
residence, marital status and occupation using defini-
tions adapted from those used in the Uganda Demo-
graphic Health Survey reports [17]; 2) Baseline Clinical
data, that is, body mass index (BMI) defined as low if
<18.5 kg/m2 [18], sputum bacterial load using the World
Health Organization (WHO) grading for LJ culture [19],
time-to-detection of MTB on MGIT culture at baseline
categorized into a binary variable using a cut-off of
14 days [20], hemoglobin level defined as low if <11 g/
dL for males and ≤10.4 g/dl for females [21].
We fitted univariable and multivariable binomial re-
gression models to establish the predictors of culture
non-conversion at month-2. Variables associated with
P < 0.4 in univariable analysis were included in the ini-
tial multivariable model after establishing the absence of
multi-collinearity. The final model was systematically ad-
justed on treatment regimen, age, gender and baseline
colony density. A 5% significance level was used. Tests
for interaction and goodness-of-fit were performed.
Results
One hundred enrolled patients in Uganda had their spu-
tum evaluated at different time points (Figure 1). The
participants were predominantly males (80%) with a
mean age of 36.2 years. They had a mean body weight of
51 kg and 44% were underweight (BMI < 18.5Kg/m2).
Predominantly, patients had high bacillary loads of 2+
and above (87%) and high colony density of 3+ and
above in LJ (80%). Overall, mean TTD of MTB on
MGIT was 13.4 ± 10.6 days (Range: 3–51 days), with 65
out of 95 (68.4%) patients showing MTB growth within
14 days from MGIT inoculation at baseline. Majority of
patients with baseline colony density of >2+ or ≤2+, had
a TTD on MGIT of less than 14 days (79%) and above
14 days (72%), respectively, p < 0.0001. Three patients
(3%) had isoniazid mono-resistance (Table 1).
Overall, using both LJ and MGIT, 45% had converted on
culture by month-2. Culture conversion was 50%, 40.6%
and 44.1% for patients in the 10, 15 and 20 mg/Kg rifam-
picin arms, respectively, p = 0.721 (Table 2). It increased
to 91.2%, 83.3% and 86.7% at month-4 (p = 0.685). All pa-
tients were culture negative at month-6.
Contamination was reported in 5/99 (5.1%), 2/93 (2.2%)
and 0/90 (0%) of the patients with LJ done at month-2, 4
and 6 respectively. On the other-hand, contamination was
reported in 3/85 (3.5%) patients with MGIT performed at
Fig. 1 Study Profile
Atwine et al. BMC Infectious Diseases  (2017) 17:299 Page 3 of 8
month-6. No MGIT contamination was noted before
month 6 follow-up. None of the patients had contamin-
ation on both LJ and MGIT at the same visit.
The overall estimates of culture conversion by LJ were
higher than with MGIT at months 2 (56.0% vs 48.4%,
p = 0.0707) and month-4 (98.9% vs 88.4%, p = 0.0391)
(Table2). Although none showed statistical significance
the differences in conversion rates between LJ and
MGIT at month-2 seem more higher within patients in
high-dose rifampicin arms (10% for 15 mg/Kg and 14.1%
for 20 mg/Kg) than patients in the control arm (−1.5%).
TDD of MTB on baseline MGIT culture and occupa-
tion were significantly associated with the culture non-
conversion at month-2 after adjusting for age, gender,
treatment regimen, and baseline colon density. Patients
with baseline TTD below 14 days had a 2-fold increased
risk of month-2 non-conversion as compared to those
with TTD of 14 days and above, (aRR = 2.1, [95% CI:
[1.18–3.93], p = 0.013). On the other-hand, within occu-
pations, patients working in “social service jobs”, which
in this study accounts mostly for motor-bike passenger
Table 1 Participants’ baseline characteristics
Characteristic Number
Mean age in years (SD) 100 36.2 (11.6)
Age categories, n (%)
18–24 20 (20.0)
25–49 64 (64.0)
> =50 16 (16.0)
Gender, male, n (%) 100 80 (80.0)








Unskilled manual 37 (40.2)
Student 6 (6.5)
Business 6 (6.5)








Relationship with Domiciliary treatment
monitor, n (%)
97
Parental family 42 (43.3)
Own family 22 (22.7)
Friends/in-laws 33 (34.0)
Current smoker, n (%) 89 35 (39.3)
TB treatment regimen, n (%) 100
Standard regimen (R10mg/kg) 33 (33.0)
Regimen 1 (R15mg/kg) 33 (33.0)
Regimen 2 (R20mg/kg) 34 (34.0)
Clinical Parameters
Mean body weight in kg (SD) 100 51.2 (7.8)
Mean BMI in Kg/m2 (SD) 99 19.0 (2.4)
BMI <18.5, n (%) 44 (44.4)
Biochemical parameters
Mean hemoglobin in g/dl (SD) 100 11.7 (1.8)
Hemoglobin gradeb
Mild anemia, n (%) 13 (13.0)
Moderate anemia, n (%) 11 (11.0)
Table 1 Participants’ baseline characteristics (Continued)
Severe anemia, n (%) 6 (6.0)
Biological Parameters





Baseline LJ positivity, n (%) 100 98 (98.0)






Baseline MGIT positivity, n (%) 100 95 (95.0)
Baseline combined LJ/MGIT positivity, n (%) 100 100 (100.0)
Mean Time-to-detection (TDD) of MTB on MGIT
in days (±SD)
95 13.4 ± 10.6
TDD of MTB on MGIT in days, <14 days, n (%) 95 65 (68.4)
Primary Isoniazid resistance, n (%) 100 3 (3.0)
SD standard deviation, BMI body mass index, LJ Löwenstein-Jensen, MGIT,
mycobacterium growth indicator tube, MTB mycobacterium tuberculosis complex
aOccupation: 1) Peasant represents people earning from agriculture; 2)
professional represents those working in certified, managerial or technical
jobs; 3) Social service representing mainly transport services like motor-bike
riders and those in unskilled manual (like bar/restaurant attendants, house
maids, truck attendants); 4) Students representing those still in school and not
working; 5) Business representing those involved in their own businesses.
bHemoglobin: Mild (male:10–10.9 g/dl, Female: 9.5–10.4), Moderate (Male: 9.0-
< 10.0, Female: 8.5- < 9.5), Severe (Male:7.0- < 9.0, Female: 6.5- < 8.5based on
Division of AIDS (DAIDS) guideline
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riders, were significantly associated with a 3-fold in-
creased risk of month-2 culture non-conversion (RR = 3.0,
[95% CI:1.11–8.19], p = 0.031) as compared to those in
formal professional jobs (Table 3).
Discussion
This sub-analysis of the data from Ugandan site within the
Rifatox trial, shows that the low culture conversion at
month-2 was due to delayed culture conversion and not
treatment failure. Indeed, 87.2% of patients converted by
month-4 and 100% by month-6 without initiation of
second-line treatment. Culture non-conversion at month-2
suffers a lower specificity in predicting TB relapse or treat-
ment failure [22] a phenomenon partially observed in our
study given that all month-2 non-converters finally con-
verted by month 6. No significant differences were ob-
served in the conversion rates across 10, 15 and 20 mg/kg
rifampicin-based regimens using LJ, MGIT or combination
of LJ and MGIT. Despite the low sample size on which this
sub-analysis was performed, these results are consistent
with what was reported in the Rifatox trial using LJ culture
only [16]. However, given the good safety results of high-
dose rifampicin shown in two recent trials [16, 23] and the
difficulty to rely on month-2 culture conversion as surro-
gate endpoint of treatment efficacy [24–26], a phase3 effi-
cacy trial of 4 month regimens based on high-dose
rifampicin is under implementation. This Rifashort trial
(NCT02581527) will evaluate 1200 mg and 1800 mg rifam-
picin daily in the reduction of treatment duration for pul-
monary tuberculosis from 6 months to 4 months.
The observed combined LJ/MGIT month-2 culture con-
version rate (45%), was lower than that reported (61%) in
another trial that involved patients in Central Uganda [14].
The slow conversion rates may partly be explained by the
fact that majority of the patients (>80%) had high baseline
bacillary load and colony density. The absence of associ-
ation between baseline sputum bacterial load and the ab-
sence of culture conversion at Month 2 is possibly hidden
by the selection of smear-positive patients and by a very
high proportion of patients with high bacterial load overall.
This is a reflection of late medical consultation or delayed
TB diagnosis among TB patients. Delayed culture conver-
sion may potentially elongate patients’ period of infectious-
ness, a challenge in TB control efforts. Unfortunately, since
patients were not followed up after completion of treatment
in the Rifatox phase2 trial, it was not possible to report on
whether delayed sputum converters also had a higher risk
of relapse than early converters. On a positive side, this will
also be assessed within the Rifashort trial.
Our study noted a 2-fold increase in risk of culture non-
conversion at month-2 in patients with baseline TTD of
MTB on MGIT below 14 days as compared to those with
TTD of 14 days or above [10]. This difference may par-
tially be due to the high bacillary colony density prior to
Table 2 Culture conversion by culture method and treatment arm at month-2, 4 and 6
Month Culture Overall Treatment Arm









Month-2 LJ 51/91 (56.0) 17/32 (53.1) 14/27 (51.9) 20/32 (62.5) 0.697
MGIT 46/95 (48.4) 18/33 (54.6) 13/31 (41.9) 15/31 (48.4) 0.601
% difference 7.6 −1.5 10 14.1
p-valuea 0.0707 1.0000 0.1250 0.2891
Both LJ and MGIT 45/100 (45.0) 17/34 (50.0) 13/32 (40.6) 15/34 (44.1) 0.721
Month-4 LJ 88/89 (98.9) 31/31 (100.0) 28/29 (96.6) 29/29 (100.0) 0.652
MGIT 76/86 (88.4) 29/32 (90.6) 24/27 (88.9) 23/27 (85.2) 0.913
% difference 10.5 9.4 7.7 14.8
p-valuea 0.0391 0.5000 0.6250 0.2500
Both LJ and MGIT 82/94 (87.2) 31/34 (91.2) 25/30 (83.3) 26/30 (86.7) 0.685
Month-6 LJ 87/87 (100.0) 33/33 (100.0) 26/26 (100.0) 28/28 (100.0) NA
MGIT 78/78 (100.0) 29/29 (100.0) 26/26 (100.0) 23/23 (100.0) NA
% difference 0.0 0.0 0.0 0.0
p-valuea 1.0000 1.0000 1.0000 1.0000
Both LJ and MGIT 88/88 (100.0) 34/34 (100.0) 26/26 (100.0) 28/28 (100.0) NA
aExact McNemar p-value
bFishers’ exact p-value
Converted culture converted, CR control regimen (10 mg/kg rifampicin), SR1 study regimen1 (15 mg/kg rifampicin), SR2 study regimen2 (20 mg/kg rifampicin), LJ
Löwenstein-Jensen, MGIT mycobacterium growth indicator tube
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Age in years, n = 100
18–45 36 (43.4) 47 (56.6) 1.2 [0.70–2.06] 0.6 [0.32–1.32]
> 45 9 (52.9) 8 (47.1) 1.0 1.0
Gender, n = 100
Female 10 (50.0) 10 (50.0) 1.0 1.0
Male 35 (43.8) 45 (56.3) 1.1 [0.70–1.82] 1.1 [0.60–2.06]
Marital status, n = 92
Married 26 (48.2) 28 (51.9) 1.0 [0.67–1.61]
Separated/Divorced 2 (25.0) 6 (75.0) 1.5 [0.88–2.57]
Single/widowed 15 (50.0) 15 (50.0) 1.0
Occupation, n = 92
Peasant 11 (68.8) 5 (31.3) 0.9 [0.29–3.04] 0.8 [0.26–2.65]
Professional 6 (66.7) 3 (33.3) 1.0 1.0
Social service 3 (16.7) 15 (83.3) 2.5 [0.97–6.44] 3.0 [1.10–8.19]
Unskilled manual 17 (46.0) 20 (54.1) 1.6 [0.61–4.28] a1.5 [0.56–3.78]
Student 3 (50.0) 3 (50.0) 1.5 [0.44–5.09] 2.1 [0.61–7.11]
Business 3 (50.0) 3 (50.0) 1.5 [0.44–5.09] 1.3 [0.40–4.36]
District of residence, N = 100
Bushenyi 5 (55.6) 4 (44.4) 1.0
Isingiro 8 (38.1) 13 (61.9) 1.4 [0.62–3.11]
Mbarara 32 (45.7) 38 (54.3) 1.2 [0.57–2.62]
Current Smoker, n = 89 15 (42.9) 20 (57.1) 1.1 [0.74–1.62]
TB treatment regimen, n = 100
Standard regimen 17 (50.0) 17 (50.0) 1.0 1.0
Regimen 1 13 (40.6) 19 (59.4) 1.5 [0.55–3.87] 0.8 [0.45–1.34]
Regimen 2 15 (44.1) 19 (55.9) 1.3 [0.49–3.29] 1.1 [0.69–1.84]
Body mass index in kg/m2, n = 99
18.5 and above 25 (45.5) 30 (54.6) 1.0
< 18.5 20 (45.5) 24 (54.6) 1.0 [0.70–1.44]
Colony density at baseline, n = 98
1+ 2 (50.0) 2 (50.0) 1.0 1.0
2+ 8 (57.1) 6 (42.9) 0.9 [0.27–2.71] 0.5 [0.12–2.01]
3+ 23 (41.1) 33 (58.9) 1.2 [0.43–3.22] 0.5 [0.11–1.82]
4+ 11 (45.8) 13 (54.2) 1.1 [0.38–3.09] 0.4 [0.09–1.44]
Time-to-detection (TDD) of MTB on MGIT at baseline
Less than 14 days 24 (36.9) 41 (63.1) 1.6 [0.98–2.54] 2.1 [1.18–3.93]b
14 days and above 18 (60.0) 12 (40.0) 1.0 1.0
Hemoglobin levels, n = 100
Normal 28 (40.0) 42 (60.0) 1.0
Low 17 (56.7) 13 (43.3) 0.7 [0.46–1.13]
Missed atleast a dose in first 2 months, n = 100 3 (23.1) 10 (76.9) 1.5 [1.04–2.13]
Multivariable model characteristics: N = 87, deviance = 100.63, Binomial model-based goodness of fit, p = 0.0177, Logit model-based goodness of fit, p = 0.5291
RR crude risk ratio, aRR adjusted risk ratio, 95% CI 95% Confidence Interval, LJ Löwenstein-Jensen, MGIT mycobacterium growth indicator tube, NA not applicable,
MTB mycobacterium tuberculosis ap = 0.031; bp = 0.013
Atwine et al. BMC Infectious Diseases  (2017) 17:299 Page 6 of 8
treatment (80% > 2+). However, it is interesting to note
that the significant association remained after adjustment
on baseline colony density. On the other-hand, baseline
colony density showed no significant association with cul-
ture non-conversion at month-2, a finding that could be
explained by an overwhelmingly higher proportion of pa-
tients with high colony density (>80%) in this study. The
3-fold increase in risk of culture non-conversion at
month-2 noted in our study among patients employed in
social service jobs (mainly commercial motor-bike passen-
ger riders) as compared to those in formal professional
employment, shows the role of social factors and the need
for their consideration within TB treatment efficacy trials.
The Motor-bike passenger riders have a great social
sphere of interaction, and may play a key role in TB trans-
mission within urban and semi-urban settings. Further ex-
ploration into the reasons underlying the increased
vulnerability of this population group is needed.
This sub-study confirms the slow bacteriological re-
sponse to treatment or the presence of persister bacilli
populations reported among African patients, something
that has complicated the estimation of early TB chemo-
therapy efficacy in a number of multi-centric clinical tri-
als [1, 2, 16, 27]. Indeed, this delayed conversion among
Ugandan patients, offers more evidence to the sugges-
tion made in the retrospective study of several phase
3 TB trials conducted by the British Medical Council in
Hong Kong and East Africa, recommending the use of
month-3 instead of month-2 culture conversion end-
point as a surrogate of treatment efficacy within the
phase II East African trials [26].
As expected, LJ which is known to be a less sensitive
culture method than MGIT had a 10% higher month-2
culture conversion rate as compared to MGIT. The sig-
nificantly high overall difference in conversion rates be-
tween LJ and MGIT especially at month4, only confirms
the declining sensitivity of LJ in detecting TB with declin-
ing bacillary loads during treatment follow-up, a finding
also consistent with other studies [1, 15, 28]. It highlights
the necessity to consistently use the same culture methods
for early treatment efficacy endpoints across sites within a
TB clinical trial. This approach, will not affect the compar-
isons of the conversion rates between treatment arms.
Likewise, culture conversion rates across clinical trials can
easily be compared or pooled as long as they are based on
the same culture method. Also, our results do not support
the need to combine LJ and MGIT cultures in the same
trial for the microbiological outcome assessment. How-
ever, this would require to be further assessed in a larger
study. Surprisingly, this effect of culture media used, seem
higher and faster in the high rifampicin dose groups, with
bigger differences in TB conversion rates between LJ and
MGIT manifesting as earlier as month-2 of treatment
follow-up, a phenomenon that may perhaps be explained
by a faster reduction in LJ sensitivity following a more
rapid decline in bacilli population due to higher doses of
rifampicin [13].
The study has several limitations: i) Since it was a sub-
study from the Ugandan site only, numbers are very
small. The small sample size reduced the power to show
a difference of culture conversion between arms or be-
tween culture methods and may have hindered signifi-
cance of some predictor variables of non-conversion.
This also may have contributed to the high deviance and
inadequate goodness of fit seen with the multivariable
binomial regression model (p = 0.0177), although a good
fit was achieved on a re-run of the final model with a
logit-based model (p = 0.5291). ii) Our study being lim-
ited to only adult HIV negative TB patient population
limits its generalizability to the HIV positive population.
Similarly, the study enrollment was limited to smear-
positive patients and the results cannot be generalized to
smear-negative culture positive TB patients. Also, being
a sub-analysis within a single site, findings cannot be
generalized to other sites from different regions. Iii)
Some variables like chest radiological findings were not
collected within the Rifatox trial and could not be ex-
plored in the analysis of predictors of non-conversion.
iv) Finally, because the Rifatox trial was a phase 2 safety
trial, post treatment culture follow-up was not part of
the trial procedures and so, we could not establish
whether the delayed converters had a higher relapse rate
than early converters.
Conclusions
The month-2 culture conversion used in phase 2 clin-
ical trials as surrogate marker of treatment efficacy is
influenced by the culture method used for monitoring
mycobacterial response to TB treatment. Therefore,
multi-centric TB therapeutic trials using early efficacy
endpoint should use the same culture method across
sites. The Time-to-detection of MTB on MGIT prior
to treatment initiation and working in Social service
jobs bear an increased risk of culture non-conversion
at month-2.
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